About Us

Jacob leads the Global Business Development Team at Inoviv, bringing 5+ years of invaluable experience to the table. His tenure at Inoviv has been marked by pioneering efforts in implementing the use of biomarkers in clinical trials across neurodegeneration, fibrosis, oncology and others. With a background in Biochemistry from Imperial College London coupled with experience in Investment Banking/M&A at Goldman Sachs, Jacob offers a unique blend of scientific acumen and business expertise. Passionate about generating key insights to accelerate the development of new medicines, Jacob is dedicated to driving innovation and forging strategic partnerships that advance healthcare outcomes.

Martin is an accomplished professional with extensive experience in bioanalysis and mass spectrometry. Currently serving as the Director of Bioanalysis at Inoviv, Martin brings a wealth of knowledge and expertise to his role. Prior to joining Inoviv, Martin served as Lead Scientist at Medicines Discovery Catapult, where he established a high-throughput mass spectrometry laboratory and played a key role in developing innovative solutions for complex analytical challenges in drug discovery and biomarker research. Martin also contributed to innovative projects as a Postdoctoral Scientist at AstraZeneca, where he played a pivotal role in the design and development of Acoustic Mist Ionisation MS (AMI-MS), a cutting-edge analytical platform that revolutionized drug discovery efforts.

Blandine is a seasoned professional with over a decade of experience in protein analysis and quantification via mass spectrometry. She has worked across diverse industries including diagnostics, pharmaceuticals, and agriculture. Before joining Inoviv as associate director of Analysis, she held technical expert roles in various companies such as BioMerieux, Sanofi Pasteur, UCB Pharma, and Syngenta. Her expertise lies in utilizing targeted and global proteomics quantitative workflows to identify biomarkers, metabolic pathways, and mechanisms of action for new molecules. Notable highlights of her career include her doctoral research at Université Claude-Bernard-Lyon-I, focusing on targeted proteomics for vaccine integrity monitoring in collaboration with Sanofi Pasteur, and her work with Sciex on novel approaches for highly multiplexed targeted mass spectrometry datasets.

Currently serving as our Director of Bioinformatics, Craig brings a wealth of experience in programming, statistical analysis and big data. Craig’s bioinformatics journey spans over decades, most notably at the University of Manchester, where he held various roles including Bioinformatics Senior Experimental Officer at the Wellcome Trust Centre for Cell Matrix Research and spearheaded the Wellcome Trust’s multi-million-dollar discovery bioinformatics strategy. Furthermore, Craig has also developed tools for surrogate peptide selection in quantitative proteomics and designed pipelines for QconCAT technology, enabling absolute protein quantification in yeast. Craig’s expertise also extends to processing and analyzing mass spectrometry data using various pipelines (mProphet, Skyline, MaxQuant, Progenesis, PLGS, Mass Lynx, DanteR), as well as next-generation RNA-sequencing analysis.